Sun Pharma Pursues $11.75 Billion Acquisition of Organon in Landmark Overseas Deal

The Sun Pharmaceutical Industries has revealed the ambitious plan to acquire the US-based Organon & Co. for the $11.75 billion in an all-cash transaction. This acquisition will marks one of the largest overseas takeovers by the any Indian firm. With this it will strengthening the India’s presence in the global pharmaceutical industry.

India’s Biggest Pharma Deal: Key Highlights

Under the new agreement the Sun Pharma will acquire all the outstanding shares of Organon at $14 per share.

The deal has received the approval from the boards of both companies and it is expected to close by early to the 2027 with subject to the regulatory and shareholder approvals.

This announcement have triggered the strong market reaction as the Sun Pharma’s shares rising over the 7%.

Strategic Expansion into Global Markets

The acquisition of the Organon & Co. significantly expands the Sun Pharma’s global footprint.

Organon operates the,

• Total 6 manufacturing facilities across the European Union and emerging markets.
• Also had the portfolio of 70+ products.
• Their presence in over the 140 countries.

After the post-acquisition the combined entity is to be expected to operate in the 150 countries and will make the Sun Pharma a truly global pharmaceutical powerhouse.

Boost to Women’s Health and Biosimilars

One of the most important aspects of this deal is to focus on to the high-growth segments.

In the Women’s Health Sun Pharma is set to become the top-three global player.

Also in the Biosimilars the company will rank as the 7th largest worldwide.

This diversification will reduces the dependency on to the traditional generics and positions the company in to the future-oriented pharmaceutical segments.

Financial Strength and Synergies

Organon reported the

• Revenue about $6.2 billion in the year 2025.
• Also had the adjusted EBITDA in $1.9 billion.
• And also had the debt around $8.6 billion.

The combined company will have to be have estimated revenues of the $12.4 billion and will place it among the top 25 global pharma companies.

What are Biosimilars?

Biosimilars are medicines which are highly similar to the already approved biological drugs but they are typically more affordable.

They are important because they,

• Increase the access to the advanced treatments.
• Also reduce the healthcare costs.
• And it will promote the competition in to the pharmaceutical market.